BioVie to Present Parkinson's Study Data at AD/PD 2026 Conference.

BioVie Inc's lead candidate, bezisterim (NE3107), will be presented at the AD/PD 2026 conference. The abstract, titled "Demographics and Baseline Characteristics of Participants in a Study of Bezisterim (NE3107) in Early Parkinson’s Disease (SUNRISE-PD)," summarizes initial data from the SUNRISE-PD study. Topline results are expected in mid-2026. Bezisterim is an oral drug designed to reduce inflammation and improve insulin sensitivity without suppressing the immune system.